Please login to the form below

Not currently logged in
Email:
Password:

Amgen appoints Jonathan M Peacock as CFO

Amgen has appointed Jonathan M Peacock to the role of chief financial officer with effect from September 1, 2010

Amgen has appointed Jonathan M Peacock to the role of chief financial officer (CFO) with effect from September 1, 2010. He will take over the role from Michael A Kelly, who has served as acting CFO since May 2010. Peacock will have responsibility for Amgen's finance and investor relations operations, and will report to Amgen's chairman and CEO, Kevin W Sharer.

Peacock will join from Novartis, where he has held the role of CFO and administration officer since 2005, leading the finance, information technology, purchasing, strategic planning and mergers and acquisitions functions.

Speaking about the appointment, Sharer said: "I am delighted to have a leader of Jonathan's talent, vision and international experience join Amgen at a time when we are expanding globally."

A qualified accountant with an MA in economics from the University of St Andrews in Scotland, Peacock has previous experience as a partner at McKinsey and Company, where he was co-leader of the European corporate finance practice working in the consulting firm's Amsterdam, Zurich and London offices. He was also a partner at Price Waterhouse in New York and London. 

15th July 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...

Infographics